Biological systems involved in disease are inherently complex and targeting a single receptor/ligand interaction or an individual pathway employing monotherapy often does not mediate maximal therapeutic benefit. Cancer immunotherapy results have shown that a combination of two separate antibodies can produce improved clinical outcomes as compared to monotherapy. There is a pressing medical need to develop technology that enables interdiction of multiple pathways by efficiently producing a single drug product that contains more that one therapeutic antibody.
Sound Biologics is building a new technology platform to produce the next generation of therapeutic antibodies that are capable of targeting multiple molecules and pathways. Our proprietary MabPair platform enables the development of custom-designed antibody combinations that bring the synergy of a two full-antibody combination and reduce the opportunity for tumor escape and drug resistance. The MabPair platform also offers the advantages regarding convenience of administration and reduced cost when compared to conventional antibody combination therapies.
